|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of ABCC1 mRNA; 2-tert-butylhydroquinone results in increased expression of ABCC1 protein |
CTD |
PMID:11836020 PMID:16014739 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO EXP |
2-tert-butylhydroquinone results in increased expression of ABCC2 mRNA; 2-tert-butylhydroquinone results in increased expression of ABCC2 protein |
CTD |
PMID:11264000 PMID:11836020 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of ABCG2 mRNA; 2-tert-butylhydroquinone results in increased expression of ABCG2 protein AHR protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of ABCG2 protein] |
CTD |
PMID:17077187 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of ADH7 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO EXP |
AHR protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of ABCG2 protein]; AHR protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of UGT1A6 mRNA] 2-tert-butylhydroquinone results in increased activity of and results in increased localization of AHR protein |
CTD |
PMID:12948865 PMID:15608132 PMID:17077187 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of AKR1B10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of AKR1C1 mRNA |
CTD |
PMID:9973208 PMID:30806763 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:23112101 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; 2-tert-butylhydroquinone inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [thallium nitrate results in decreased expression of ATP5F1A protein] |
CTD |
PMID:31726083 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
B4galt1 |
beta-1,4-galactosyltransferase 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of B4GALT1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
affects localization multiple interactions |
ISO |
2-tert-butylhydroquinone affects the localization of BACH1 protein 2-tert-butylhydroquinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein]; [ferric chloride results in increased oxidation of 2-tert-butylhydroquinone] promotes the reaction [2-tert-butylhydroquinone analog binds to BACH1 protein] |
CTD |
PMID:28645578 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
2-tert-butylhydroquinone results in decreased expression of BAX protein [2-tert-butylhydroquinone results in increased stability of NFE2L2 protein] which results in decreased expression of BAX protein 2-tert-butylhydroquinone inhibits the reaction [sodium arsenite results in increased expression of BAX protein] 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of BAX protein]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in increased expression of BAX protein] |
CTD |
PMID:22275372 PMID:26878773 PMID:28583816 PMID:32565124 PMID:37075934 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to BCL2 promoter]; [2-tert-butylhydroquinone results in increased stability of NFE2L2 protein] which results in increased expression of BCL2 protein; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of BCL2 mRNA] 2-tert-butylhydroquinone results in increased expression of BCL2 protein 2-tert-butylhydroquinone results in increased expression of BCL2 mRNA; 2-tert-butylhydroquinone results in increased expression of BCL2 protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; 2-tert-butylhydroquinone inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein] 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in decreased expression of BCL2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of BCL2 protein] |
CTD |
PMID:22275372 PMID:26878773 PMID:28583816 PMID:31423616 PMID:32565124 PMID:37075934 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bco2 |
beta-carotene oxygenase 2 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of BCO2 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 8:50,882,174...50,907,676
Ensembl chr 8:50,882,181...50,915,467
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of BLVRB mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of CASP3 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; 2-tert-butylhydroquinone inhibits the reaction [hydroquinone results in increased cleavage of CASP3 protein]; 2-tert-butylhydroquinone inhibits the reaction [pterostilbene results in increased activity of CASP3 protein]; 2-tert-butylhydroquinone inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; solanesol promotes the reaction [2-tert-butylhydroquinone inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein]] 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased cleavage of CASP3 protein] |
CTD |
PMID:22275372 PMID:25341683 PMID:25645596 PMID:26878773 PMID:28583816 PMID:31423616 PMID:32073640 PMID:32428544 PMID:32565124 PMID:35123993 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [pterostilbene results in increased activity of CASP4 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein] |
CTD |
PMID:22275372 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of CAT mRNA] 2-tert-butylhydroquinone results in increased activity of CAT protein |
CTD |
PMID:26878773 PMID:32428544 PMID:32565124 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CBR3 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CCL2 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CCL20 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases secretion |
ISO |
2-tert-butylhydroquinone results in increased secretion of CCL5 protein |
CTD |
PMID:30806763 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of CCN2 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of CCND1 protein 2-tert-butylhydroquinone promotes the reaction [sodium arsenite results in increased expression of CCND1 protein] |
CTD |
PMID:26878773 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd5l |
Cd5 molecule-like |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CD5L mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein] |
CTD |
PMID:30171972 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CD86 protein |
CTD |
PMID:19033392 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions increases expression |
ISO |
2-tert-butylhydroquinone inhibits the reaction [sodium arsenite results in decreased expression of CDK4 protein] 2-tert-butylhydroquinone results in increased expression of CDK4 protein |
CTD |
PMID:26878773 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of and results in increased activity of CES1 protein alternative form; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of CES1 mRNA alternative form] |
CTD |
PMID:19715681 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [CREBBP protein binds to NFE2L2 protein]]; 2-tert-butylhydroquinone promotes the reaction [CREBBP protein binds to NFE2L2 protein]; Egtazic Acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [CREBBP protein binds to NFE2L2 protein]] |
CTD |
PMID:21443188 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Creg2 |
cellular repressor of E1A-stimulated genes 2 |
affects response to substance |
ISO |
CREG2 gene SNP affects the susceptibility to 2-tert-butylhydroquinone |
CTD |
PMID:25622337 |
|
NCBI chr 9:41,872,000...41,945,413
Ensembl chr 9:41,902,304...41,945,095
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of AKT1 protein]; 2-tert-butylhydroquinone inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased secretion of HMGB1 protein]; [2-tert-butylhydroquinone co-treated with CSF1 protein co-treated with TNFSF11 protein] results in decreased expression of CSF1R protein; [2-tert-butylhydroquinone co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of HMOX1 protein; [TNFSF11 protein co-treated with CSF1 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of CTSK protein; [TNFSF11 protein co-treated with CSF1 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of NFATC1 protein |
CTD |
PMID:23112101 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[2-tert-butylhydroquinone co-treated with CSF1 protein co-treated with TNFSF11 protein] results in decreased expression of CSF1R protein; [TNFSF11 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of CSF1R protein |
CTD |
PMID:23112101 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
[TNFSF11 protein co-treated with CSF1 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of CTSK protein |
CTD |
PMID:23112101 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cul3 |
cullin 3 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to CUL3 protein] |
CTD |
PMID:18417180 PMID:30261176 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CXCL1 mRNA |
CTD |
PMID:30806763 PMID:35724838 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CXCL2 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CXCL1 mRNA |
CTD |
PMID:30806763 PMID:35724838 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyb5a |
cytochrome b5 type A |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CYB5A mRNA |
CTD |
PMID:16014739 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in increased expression of CYBB protein] |
CTD |
PMID:28844481 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of CYCS protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the localization of CYCS protein]; 2-tert-butylhydroquinone inhibits the reaction [hydroquinone results in increased expression of CYCS protein] |
CTD |
PMID:31423616 PMID:35123993 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of CYP11A1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of CYP11A1 protein] |
CTD |
PMID:32565124 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO |
2-tert-butylhydroquinone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; 2-tert-butylhydroquinone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; 2-tert-butylhydroquinone promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; 2-tert-butylhydroquinone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; FH535 inhibits the reaction [2-tert-butylhydroquinone results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [2-tert-butylhydroquinone results in increased activity of CYP1A1 protein]; resveratrol inhibits the reaction [2-tert-butylhydroquinone results in increased expression of CYP1A1 mRNA] 2-tert-butylhydroquinone results in increased expression of and results in increased activity of CYP1A1 protein; resveratrol inhibits the reaction [2-tert-butylhydroquinone results in increased activity of CYP1A1 protein] |
CTD |
PMID:9973208 PMID:15608132 PMID:15627257 PMID:16581943 PMID:25174530 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of CYP2C19 mRNA; 2-tert-butylhydroquinone results in increased expression of CYP2C19 protein |
CTD |
PMID:24830941 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
2-tert-butylhydroquinone inhibits the reaction [pterostilbene results in increased expression of DDIT3 protein] 2-tert-butylhydroquinone results in increased expression of DDIT3 protein |
CTD |
PMID:25341683 PMID:35724838 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dsc3 |
desmocollin 3 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of DSC3 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr18:11,379,759...11,413,797
Ensembl chr18:11,377,347...11,413,797
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of DUSP1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of EDN1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein] |
CTD |
PMID:36343453 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [pterostilbene results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression multiple interactions |
EXP ISO |
2-tert-butylhydroquinone results in increased expression of EPHX1 mRNA 2-tert-butylhydroquinone results in increased expression of EPHX1 exon; 2-tert-butylhydroquinone results in increased expression of EPHX1 protein alternative form NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of EPHX1 exon] |
CTD |
PMID:20650352 PMID:24704207 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Esd |
esterase D |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of ESD mRNA |
CTD |
PMID:16014739 |
|
NCBI chr15:50,043,634...50,063,134
Ensembl chr15:50,043,632...50,063,144
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
2-tert-butylhydroquinone binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
2-tert-butylhydroquinone promotes the reaction [FGF1 protein results in increased abundance of and results in increased secretion of Glutathione]; FGF1 protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein] |
CTD |
PMID:16524372 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of FGF18 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
2-tert-butylhydroquinone results in increased expression of FOS protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [2-tert-butylhydroquinone results in increased expression of FOS protein]; 2-tert-butylhydroquinone promotes the reaction [FOS protein binds to CYP2C9 promoter] 2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in increased expression of FOS protein] |
CTD |
PMID:24830941 PMID:28844481 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of FSHB protein] |
CTD |
PMID:32565124 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2-tert-butylhydroquinone results in increased expression of FTH1 mRNA]; PTEN protein affects the reaction [2-tert-butylhydroquinone results in increased expression of FTH1 mRNA]; wortmannin inhibits the reaction [2-tert-butylhydroquinone results in increased expression of FTH1 mRNA] |
CTD |
PMID:23829535 PMID:25003661 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of FTL1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Ftmt |
ferritin mitochondrial |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of FTMT mRNA |
CTD |
PMID:15664434 |
|
NCBI chr18:45,758,874...45,760,123
Ensembl chr18:45,758,874...45,760,123
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Streptozocin results in decreased expression of G6PD mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Streptozocin results in decreased expression of G6PD protein] |
CTD |
PMID:35478295 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabpa |
GA binding protein transcription factor subunit alpha |
affects localization |
ISO |
2-tert-butylhydroquinone affects the localization of GABPA protein |
CTD |
PMID:16308312 |
|
NCBI chr11:23,888,586...23,917,612
Ensembl chr11:23,888,815...23,917,605
|
|
G |
Gata3 |
GATA binding protein 3 |
increases activity |
ISO |
[2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased activity of GATA3 protein |
CTD |
PMID:22250088 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
affects expression increases expression increases activity multiple interactions decreases expression |
ISO EXP |
2-tert-butylhydroquinone affects the expression of GCLC mRNA 2-tert-butylhydroquinone results in increased expression of GCLC mRNA 2-tert-butylhydroquinone results in increased activity of GCLC protein 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of GCLC mRNA]; [2-tert-butylhydroquinone results in increased activity of GCLC protein] which results in increased abundance of Glutathione; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA] 2-tert-butylhydroquinone results in decreased expression of GCLC mRNA |
CTD |
PMID:7955076 PMID:10978506 PMID:12007577 PMID:15946948 PMID:16014739 PMID:17980396 PMID:19183254 PMID:19328227 PMID:22250088 PMID:23906629 PMID:24128855 PMID:27178040 PMID:30547568 PMID:30806763 PMID:32428544 PMID:35724838 More...
|
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of GCLM mRNA] 2-tert-butylhydroquinone promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of GCLM mRNA]; [2,2',4,4'-tetrabromodiphenyl ether co-treated with 2-tert-butylhydroquinone] results in increased expression of GCLM mRNA 2-tert-butylhydroquinone results in decreased expression of GCLM mRNA |
CTD |
PMID:10978506 PMID:12007577 PMID:12081989 PMID:16014739 PMID:19183254 PMID:19328227 PMID:24632381 PMID:25003661 PMID:25305463 PMID:30547568 PMID:35724838 More...
|
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpr87 |
G protein-coupled receptor 87 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of GPR87 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 2:143,439,741...143,440,901
Ensembl chr 2:143,439,735...143,458,190
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [Matrines results in increased expression of GPT protein] |
CTD |
PMID:37716422 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression multiple interactions |
EXP |
2-tert-butylhydroquinone results in increased expression of GPX1 protein 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of GPX1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of GPX1 protein] |
CTD |
PMID:28583816 PMID:32565124 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression multiple interactions |
ISO EXP |
2-tert-butylhydroquinone results in increased expression of GPX4 mRNA; 2-tert-butylhydroquinone results in increased expression of GPX4 protein 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of GPX4 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of GPX4 protein] 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of GPX4 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of GPX4 protein] |
CTD |
PMID:37393915 PMID:37716422 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of GRIA1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases activity multiple interactions |
ISO EXP |
2-tert-butylhydroquinone results in increased activity of GSR protein 2-tert-butylhydroquinone inhibits the reaction [sodium arsenite results in decreased activity of GSR protein] 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased activity of GSR protein] |
CTD |
PMID:12572858 PMID:24970285 PMID:32565124 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
increases expression multiple interactions |
ISO EXP |
2-tert-butylhydroquinone results in increased expression of GSS mRNA [2-tert-butylhydroquinone co-treated with Cisplatin] results in increased expression of GSS mRNA |
CTD |
PMID:10978506 PMID:19183254 PMID:32428544 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
EXP |
2-tert-butylhydroquinone results in increased expression of GSTA2 mRNA; 2-tert-butylhydroquinone results in increased expression of GSTA2 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [2-tert-butylhydroquinone results in increased expression of GSTA2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GSTA2]; 2-tert-butylhydroquinone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; 2-tert-butylhydroquinone results in increased expression of and results in increased activity of GSTA2 protein; [S-Nitroso-N-Acetylpenicillamine co-treated with 2-tert-butylhydroquinone] results in increased expression of GSTA2; Dexamethasone promotes the reaction [2-tert-butylhydroquinone results in increased expression of and results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [2-tert-butylhydroquinone results in increased expression of GSTA2 mRNA]; N-acetylsphingosine inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GSTA2 protein] |
CTD |
PMID:7587946 PMID:12242683 PMID:15155840 PMID:15319326 PMID:15357004 PMID:15870285 More...
|
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases expression increases activity multiple interactions |
EXP ISO |
2-tert-butylhydroquinone results in increased expression of GSTA5 mRNA 2-tert-butylhydroquinone results in increased expression of GSTA1 mRNA 2-tert-butylhydroquinone results in increased activity of GSTA1 protein Tetradecanoylphorbol Acetate promotes the reaction [2-tert-butylhydroquinone results in increased expression of GSTA1 mRNA] |
CTD |
PMID:7568053 PMID:15627257 PMID:16014739 PMID:20650352 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of GSTM1 protein [2-tert-butylhydroquinone co-treated with Cisplatin] results in increased expression of GSTM1 mRNA 2-tert-butylhydroquinone results in increased expression of GSTM1 mRNA |
CTD |
PMID:21443188 PMID:32428544 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
EXP ISO |
2-tert-butylhydroquinone results in increased expression of GSTP1 protein 2-tert-butylhydroquinone results in increased expression of GSTP1 mRNA |
CTD |
PMID:12680784 PMID:15533597 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein] |
CTD |
PMID:30171972 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
EXP ISO |
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of H2AX protein] 2-tert-butylhydroquinone inhibits the reaction [hydroquinone results in increased expression of H2AX protein] 2-tert-butylhydroquinone results in increased expression of H2AX protein |
CTD |
PMID:28583816 PMID:35123993 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of HBG1 mRNA |
CTD |
PMID:21464371 |
|
NCBI chr 1:158,271,871...158,273,426
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression |
EXP |
2-tert-butylhydroquinone results in decreased expression of HES1 protein |
CTD |
PMID:29663635 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased secretion of HMGB1 protein] |
CTD |
PMID:23112101 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]]; 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; 2,2',4,4'-tetrabromodiphenyl ether promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]; 2-tert-butylhydroquinone promotes the reaction [sodium arsenite results in increased expression of HMOX1 protein]; [2-tert-butylhydroquinone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; brusatol inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein]; Calcium affects the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; Calcium Chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; Egtazic Acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]]; Egtazic Acid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; ferric chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in decreased expression of HMOX1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in decreased expression of HMOX1 protein]; 2-tert-butylhydroquinone inhibits the reaction [Paraquat results in increased expression of HMOX1 protein]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]; [2-tert-butylhydroquinone co-treated with Cisplatin] results in increased expression of HMOX1 mRNA; [2-tert-butylhydroquinone co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of HMOX1 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [TNFSF11 protein co-treated with 2-tert-butylhydroquinone] results in increased expression of HMOX1 protein; Acetylcysteine inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein]; Calcium Chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Nitrites]]; Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] 2-tert-butylhydroquinone inhibits the reaction [decamethrin results in increased expression of HMOX1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [decamethrin results in increased expression of HMOX1 protein]; 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of HMOX1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of HMOX1 protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of HMOX1 protein]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of HMOX1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of HMOX1 protein]; 2-tert-butylhydroquinone promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of HMOX1 protein]; 2-tert-butylhydroquinone promotes the reaction [thallium nitrate results in increased expression of HMOX1 protein]; [2-tert-butylhydroquinone promotes the reaction [[NFE2L2 protein binds to HMOX1 promoter] which results in increased expression of HMOX1 mRNA]] which results in decreased susceptibility to Magnesium Chloride; FGF1 protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein]; NFE2L2 gene mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein] 2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA; 2-tert-butylhydroquinone results in increased expression of HMOX1 protein |
CTD |
PMID:8612205 PMID:10473555 PMID:10874044 PMID:10975858 PMID:16014739 PMID:16524372 PMID:17676812 PMID:18227147 PMID:18417180 PMID:18482591 PMID:18512965 PMID:19033392 PMID:19715681 PMID:21107535 PMID:21443188 PMID:22250088 PMID:22493042 PMID:22983789 PMID:23112101 PMID:23906629 PMID:23942037 PMID:23945499 PMID:24128855 PMID:24970285 PMID:25003661 PMID:25305463 PMID:26878773 PMID:26879219 PMID:27012417 PMID:28264691 PMID:28583816 PMID:28645578 PMID:29663635 PMID:30476502 PMID:30547568 PMID:31726083 PMID:32073640 PMID:32428544 PMID:33465425 PMID:35724838 PMID:37075934 PMID:37393915 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:32565124 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of HSD3B1 mRNA] |
CTD |
PMID:32565124 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of HSF1 mRNA |
CTD |
PMID:30309986 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [pterostilbene results in increased expression of HSPA5 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; 2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; 2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Nitrites]; 2-tert-butylhydroquinone results in decreased expression of and results in decreased secretion of IFNG protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased expression of and results in decreased secretion of IFNG protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased expression of IFNG mRNA; HMOX1 protein promotes the reaction [2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Nitrites]]; NFE2L2 protein promotes the reaction [2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Nitrites]] |
CTD |
PMID:22250088 PMID:23942037 PMID:30171972 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in increased expression of IKBKB protein modified form] |
CTD |
PMID:28844481 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of IL10 mRNA] 2-tert-butylhydroquinone results in increased expression of IL10 mRNA |
CTD |
PMID:32565124 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12A mRNA]; 2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL12B protein binds to IL12A protein]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12A mRNA]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL12B protein binds to IL12A protein]]] |
CTD |
PMID:25680285 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; 2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL12B protein binds to IL12A protein]]; 2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL23A protein binds to IL12B protein]]; 2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL12B protein binds to IL12A protein]]] |
CTD |
PMID:25680285 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of and results in increased secretion of IL13 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of IL13 mRNA |
CTD |
PMID:22250088 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il16 |
interleukin 16 |
increases secretion |
ISO |
2-tert-butylhydroquinone results in increased secretion of IL16 protein |
CTD |
PMID:30806763 |
|
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
|
|
G |
Il17d |
interleukin 17D |
multiple interactions |
ISO |
2-tert-butylhydroquinone promotes the reaction [Oxygen deficiency results in increased expression of IL17D protein] |
CTD |
PMID:34023435 |
|
NCBI chr15:31,671,337...31,688,833
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of IL1A mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of IL1B protein]; 2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in increased expression of and results in increased secretion of IL1B protein] 2-tert-butylhydroquinone inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; 2-tert-butylhydroquinone inhibits the reaction [IL1B protein affects the localization of RELA protein]; 2-tert-butylhydroquinone inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; 2-tert-butylhydroquinone inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:28583816 PMID:28844481 PMID:35724838 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in decreased expression of IL2 mRNA 2-tert-butylhydroquinone results in decreased expression of and results in decreased secretion of IL2 protein |
CTD |
PMID:23945499 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL23A protein binds to IL12B protein]] |
CTD |
PMID:25680285 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in decreased expression of IL2RA mRNA; 2-tert-butylhydroquinone results in decreased expression of IL2RA protein 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein] |
CTD |
PMID:23945499 PMID:30171972 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of and results in increased secretion of IL4 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of IL4 mRNA 2-tert-butylhydroquinone promotes the reaction [Oxygen deficiency results in increased expression of IL4 protein] |
CTD |
PMID:22250088 PMID:34023435 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
[2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of and results in increased secretion of IL5 protein |
CTD |
PMID:22250088 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased secretion of IL6 protein]; 2-tert-butylhydroquinone promotes the reaction [Oxygen deficiency results in increased expression of IL6 protein] 2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:25305463 PMID:28844481 PMID:34023435 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases phosphorylation |
ISO |
2-tert-butylhydroquinone promotes the reaction [JUND protein binds to CYP2C9 promoter]; 2-tert-butylhydroquinone promotes the reaction [JUND protein modified form binds to CYP2C9 promoter]; JUND mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of CYP2C9 mRNA]; pyrazolanthrone inhibits the reaction [2-tert-butylhydroquinone results in increased phosphorylation of JUND protein] |
CTD |
PMID:24830941 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of KDR protein [cyanoginosin LR co-treated with 2-tert-butylhydroquinone] results in increased expression of KDR protein |
CTD |
PMID:36206955 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions increases expression affects binding decreases response to substance |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to CUL3 protein]; 2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein results in increased ubiquitination of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; KEAP1 protein mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of and results in increased activity of NFE2L2 protein]; KEAP1 protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of and results in increased activity of NFE2L2 protein] 2-tert-butylhydroquinone results in increased expression of KEAP1 protein 2-tert-butylhydroquinone binds to KEAP1 protein 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of KEAP1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of KEAP1 protein]; 2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to CUL3 protein]; 2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; [2-tert-butylhydroquinone co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; [2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in increased activity of NFE2L2 protein; Cadmium Chloride inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to KEAP1 protein]] KEAP1 protein mutant form results in decreased susceptibility to 2-tert-butylhydroquinone 2-tert-butylhydroquinone promotes the reaction [thallium nitrate results in decreased expression of KEAP1 protein] |
CTD |
PMID:18417180 PMID:18512965 PMID:19033392 PMID:19808700 PMID:23589329 PMID:30261176 PMID:31368498 PMID:31726083 PMID:32073640 More...
|
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of LHB protein] |
CTD |
PMID:32565124 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mafg |
MAF bZIP transcription factor G |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of MAFG mRNA |
CTD |
PMID:35724838 |
|
NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [2-tert-butylhydroquinone results in increased phosphorylation of MAPK1 protein]; 2-tert-butylhydroquinone inhibits the reaction [arsenite results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24830941 PMID:36343453 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [2-tert-butylhydroquinone results in increased phosphorylation of MAPK3 protein]; 2-tert-butylhydroquinone inhibits the reaction [arsenite results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24830941 PMID:36343453 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mchr1 |
melanin-concentrating hormone receptor 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of MCHR1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions increases expression |
EXP |
2-tert-butylhydroquinone inhibits the reaction [thallium nitrate results in decreased expression of MFN2 protein] 2-tert-butylhydroquinone results in increased expression of MFN2 protein |
CTD |
PMID:31726083 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions increases expression |
ISO |
2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Edetic Acid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Edetic Acid inhibits the reaction [zinc chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; zinc chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Zinc deficiency inhibits the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA] |
CTD |
PMID:14998373 PMID:19276070 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of MT2 mRNA |
CTD |
PMID:14998373 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
MTF1 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA] |
CTD |
PMID:14998373 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtrf1 |
mitochondrial translation release factor 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of MTRF1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr15:54,776,885...54,804,699
Ensembl chr15:54,776,937...54,804,704
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
[TNFSF11 protein co-treated with CSF1 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of NFATC1 protein |
CTD |
PMID:23112101 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of NFE2L1 protein |
CTD |
PMID:33838154 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects binding increases expression increases stability increases ubiquitination decreases response to substance increases activity affects response to substance affects localization increases response to substance |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [CREBBP protein binds to NFE2L2 protein]]; 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]]; 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein]; 2-tert-butylhydroquinone affects the localization of and results in increased activity of NFE2L2 protein; 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein results in increased ubiquitination of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [arsenite results in increased expression of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [CREBBP protein binds to NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [hydroquinone results in increased expression of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; 2-tert-butylhydroquinone promotes the reaction [Oxygen deficiency results in increased expression of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [pterostilbene results in increased phosphorylation of NFE2L2 protein]; 2-tert-butylhydroquinone results in increased expression of and affects the localization of NFE2L2 protein; 2-tert-butylhydroquinone results in increased expression of and results in increased activity of NFE2L2 protein; 2-tert-butylhydroquinone results in increased stability of and affects the localization of NFE2L2 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased susceptibility to arsenite; [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine; brusatol inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein]; Egtazic Acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [CREBBP protein binds to NFE2L2 protein]]; Egtazic Acid inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]]; Egtazic Acid inhibits the reaction [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein]; ferric chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein]; KEAP1 protein mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of and results in increased activity of NFE2L2 protein]; KEAP1 protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of and results in increased activity of NFE2L2 protein]; Metformin inhibits the reaction [2-tert-butylhydroquinone results in increased stability of and affects the localization of NFE2L2 protein]; NFE2L2 affects the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12A mRNA]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of [IL12B protein binds to IL12A protein]]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of EPHX1 exon]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 mutant form inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with 2-tert-butylhydroquinone] results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of CES1 mRNA alternative form] 2-tert-butylhydroquinone binds to NFE2L2 protein 2-tert-butylhydroquinone results in increased expression of NFE2L2 mRNA; 2-tert-butylhydroquinone results in increased expression of NFE2L2 protein 2-tert-butylhydroquinone results in increased stability of NFE2L2 protein 2-tert-butylhydroquinone results in increased ubiquitination of NFE2L2 protein NFE2L2 protein results in decreased susceptibility to 2-tert-butylhydroquinone 2-tert-butylhydroquinone affects the localization of and results in increased activity of NFE2L2 protein; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of and results in decreased localization of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in decreased expression of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of NFE2L2 protein]; 2-tert-butylhydroquinone results in increased expression of and results in increased localization of NFE2L2 protein; [2-tert-butylhydroquinone promotes the reaction [[NFE2L2 protein binds to HMOX1 promoter] which results in increased expression of HMOX1 mRNA]] which results in decreased susceptibility to Magnesium Chloride; [thallium nitrate co-treated with 2-tert-butylhydroquinone] results in increased expression of NFE2L2 protein; decamethrin inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein]; N-acetylsphingosine inhibits the reaction [2-tert-butylhydroquinone results in increased localization of NFE2L2 protein]; NFE2L2 gene mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 protein] 2-tert-butylhydroquinone results in increased activity of NFE2L2 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased activity of GATA3 protein 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in decreased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in decreased expression of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin affects the expression of and affects the localization of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [Paraquat results in increased expression of NFE2L2 protein]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to BCL2 promoter]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to HMOX1 promoter]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; 2-tert-butylhydroquinone results in increased expression of and affects the localization of NFE2L2 protein; [2-tert-butylhydroquinone co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; [2-tert-butylhydroquinone inhibits the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in increased activity of NFE2L2 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased activity of TBX21 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased expression of and results in decreased secretion of IFNG protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased expression of IFNG mRNA; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of and results in increased secretion of IL13 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of and results in increased secretion of IL4 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of and results in increased secretion of IL5 protein; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of IL13 mRNA; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of IL4 mRNA; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [2-tert-butylhydroquinone results in increased stability of NFE2L2 protein] which results in decreased expression of BAX protein; [2-tert-butylhydroquinone results in increased stability of NFE2L2 protein] which results in increased expression of BCL2 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 2-tert-butylhydroquinone] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [2-tert-butylhydroquinone results in increased ubiquitination of NFE2L2 protein]; Cadmium Chloride inhibits the reaction [2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to KEAP1 protein]]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of BCL2 mRNA]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Nitrites]]; NFE2L2 protein promotes the reaction [2-tert-butylhydroquinone inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitrites]] NFE2L2 protein affects the susceptibility to 2-tert-butylhydroquinone 2-tert-butylhydroquinone affects the localization of NFE2L2 protein NFE2L2 protein mutant form results in increased susceptibility to 2-tert-butylhydroquinone |
CTD |
PMID:10473555 PMID:10874044 PMID:12446695 PMID:14510636 PMID:14998373 PMID:15319326 PMID:15870285 PMID:16092930 PMID:17676812 PMID:18417180 PMID:18512965 PMID:18852027 PMID:19033392 PMID:19183254 PMID:19276070 PMID:19328227 PMID:19715681 PMID:19786557 PMID:20554019 PMID:20932822 PMID:21107535 PMID:21443188 PMID:21464371 PMID:22250088 PMID:22275372 PMID:22476201 PMID:22684020 PMID:22746536 PMID:22983789 PMID:23589329 PMID:23707609 PMID:23906629 PMID:23942037 PMID:23945499 PMID:24704207 PMID:25003661 PMID:25341683 PMID:25680285 PMID:26878773 PMID:26879219 PMID:26958860 PMID:27012417 PMID:28583816 PMID:28645578 PMID:28790194 PMID:28844481 PMID:29663635 PMID:29857117 PMID:30476502 PMID:30806763 PMID:31368498 PMID:31423616 PMID:31726083 PMID:32073640 PMID:32428544 PMID:32565124 PMID:33465425 PMID:33838154 PMID:34023435 PMID:35123993 PMID:35478295 PMID:35724838 PMID:36343453 PMID:36786954 PMID:37075934 PMID:37393915 PMID:37716422 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein] 2-tert-butylhydroquinone inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein affects the localization of NFKBIA protein] |
CTD |
PMID:28583816 PMID:35724838 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nkd1 |
NKD inhibitor of WNT signaling pathway 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of NKD1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr19:18,476,344...18,549,380
Ensembl chr19:18,476,344...18,549,380
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of NOS2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of NOS2 protein] |
CTD |
PMID:32073640 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
decreases expression |
EXP |
2-tert-butylhydroquinone results in decreased expression of NOTCH1 protein |
CTD |
PMID:29663635 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity multiple interactions increases expression decreases expression |
ISO EXP |
2-tert-butylhydroquinone results in increased activity of NQO1 protein 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; 2-tert-butylhydroquinone promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of NQO1 mRNA]; [lipopolysaccharide, E coli O55-B5 co-treated with 2-tert-butylhydroquinone] results in increased expression of NQO1 mRNA; [sodium arsenite co-treated with 2-tert-butylhydroquinone] results in increased expression of NQO1 mRNA; [sodium arsenite co-treated with 2-tert-butylhydroquinone] results in increased expression of NQO1 protein; Acetylcysteine inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; ferric chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 protein]; NFE2L2 affects the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 mutant form inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with 2-tert-butylhydroquinone] results in increased expression of NQO1 mRNA] 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of NQO1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Emodin results in decreased expression of NQO1 protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NQO1 protein]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of NQO1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of NQO1 protein]; 2-tert-butylhydroquinone promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of NQO1 protein]; 2-tert-butylhydroquinone results in increased expression of and results in increased activity of NQO1 protein; [thallium nitrate co-treated with 2-tert-butylhydroquinone] results in increased expression of NQO1 protein; Dexamethasone inhibits the reaction [2-tert-butylhydroquinone results in increased expression of and results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA] 2-tert-butylhydroquinone results in increased expression of NQO1 mRNA; 2-tert-butylhydroquinone results in increased expression of NQO1 protein 2-tert-butylhydroquinone promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; [2-tert-butylhydroquinone co-treated with Cisplatin] results in increased expression of NQO1 mRNA; [2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; AG-879 inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 mutant form inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Paraquat inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Zinc promotes the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA] 2-tert-butylhydroquinone results in decreased expression of NQO1 mRNA |
CTD |
PMID:7587946 PMID:9029048 PMID:11163336 PMID:14510636 PMID:14998373 PMID:15627257 PMID:16014739 PMID:16600132 PMID:17980396 PMID:18417180 PMID:18512965 PMID:19033392 PMID:19276070 PMID:20650352 PMID:21464371 PMID:22250088 PMID:22275372 PMID:22493042 PMID:23056183 PMID:23906629 PMID:23945499 PMID:24128855 PMID:24632381 PMID:24646717 PMID:24704207 PMID:24970285 PMID:25003661 PMID:25680285 PMID:26878773 PMID:28264691 PMID:28583816 PMID:28645578 PMID:29663635 PMID:30476502 PMID:30547568 PMID:30806763 PMID:31368498 PMID:31726083 PMID:32428544 PMID:35724838 PMID:37075934 PMID:37393915 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
2-tert-butylhydroquinone binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
2-tert-butylhydroquinone binds to and results in decreased activity of NR1I3 protein alternative form |
CTD |
PMID:20869355 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of OLR1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:31423616 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of PCNA protein] |
CTD |
PMID:32565124 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of PDGFB mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of PGD mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
2-tert-butylhydroquinone binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of PRDX1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein] |
CTD |
PMID:30171972 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of PRKACA mRNA |
CTD |
PMID:16014739 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkag2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of PRKAG2 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,010,890...10,252,142
|
|
G |
Procr |
protein C receptor |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of PROCR mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
PTEN protein affects the reaction [2-tert-butylhydroquinone results in increased expression of FTH1 mRNA] |
CTD |
PMID:23829535 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of PTGR1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
2-tert-butylhydroquinone inhibits the reaction [Emodin results in increased expression of PTGS2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of PTGS2 protein] 2-tert-butylhydroquinone inhibits the reaction [Matrines results in increased expression of PTGS2 mRNA] |
CTD |
PMID:28583816 PMID:37393915 PMID:37716422 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of REL mRNA |
CTD |
PMID:16014739 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases phosphorylation |
EXP ISO |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in increased expression of RELA mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate affects the localization of RELA protein]; 2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in increased activity of RELA protein] 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of RELA mRNA]; 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of RELA protein]; 2-tert-butylhydroquinone promotes the reaction [Particulate Matter results in decreased phosphorylation of RELA protein] 2-tert-butylhydroquinone inhibits the reaction [arsenite results in increased phosphorylation of RELA protein]; 2-tert-butylhydroquinone inhibits the reaction [IL1B protein affects the localization of RELA protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein affects the localization of RELA protein] 2-tert-butylhydroquinone results in decreased phosphorylation of RELA protein |
CTD |
PMID:28583816 PMID:28844481 PMID:32073640 PMID:32565124 PMID:35724838 PMID:36343453 PMID:36786954 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of RORC mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of SLC3A2 mRNA |
CTD |
PMID:19183254 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of SLC40A1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of SLC7A11 mRNA 2-tert-butylhydroquinone results in increased expression of SLC7A11 mRNA; 2-tert-butylhydroquinone results in increased expression of SLC7A11 protein 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of SLC7A11 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Matrines results in decreased expression of SLC7A11 protein] |
CTD |
PMID:19183254 PMID:37716422 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of SOD1 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Sodium Chloride, Dietary results in decreased expression of SOD1 protein] |
CTD |
PMID:28844481 PMID:32565124 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions |
ISO |
2-tert-butylhydroquinone results in increased expression of SOD2 mRNA [2-tert-butylhydroquinone co-treated with Cisplatin] results in increased expression of SOD2 mRNA 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the expression of SOD2 protein] 2-tert-butylhydroquinone results in increased expression of SOD2 protein |
CTD |
PMID:31423616 PMID:32428544 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp1 |
Sp1 transcription factor |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of SP1 protein |
CTD |
PMID:36206955 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sqor |
sulfide quinone oxidoreductase |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of SQOR mRNA |
CTD |
PMID:16014739 |
|
NCBI chr 3:109,841,225...109,886,724
Ensembl chr 3:109,841,250...109,960,778
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
2-tert-butylhydroquinone results in increased expression of SQSTM1 protein [thallium nitrate co-treated with 2-tert-butylhydroquinone] results in increased expression of SQSTM1 protein 2-tert-butylhydroquinone results in decreased expression of SQSTM1 mRNA |
CTD |
PMID:23589329 PMID:31726083 PMID:35724838 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[TNFSF11 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of SRC protein |
CTD |
PMID:23112101 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression decreases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of SRXN1 mRNA 2-tert-butylhydroquinone results in decreased expression of SRXN1 mRNA 2-tert-butylhydroquinone results in increased expression of SRXN1 protein |
CTD |
PMID:16014739 PMID:22003191 PMID:35724838 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of STAR mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of STAR protein] |
CTD |
PMID:32565124 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of TAP1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions |
ISO |
[2-tert-butylhydroquinone results in increased activity of NFE2L2 protein] which results in decreased activity of TBX21 protein |
CTD |
PMID:22250088 |
|
NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [arsenite results in increased expression of and results in increased secretion of TGFA protein] |
CTD |
PMID:36343453 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
2-tert-butylhydroquinone binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of TNF protein] 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of TNF mRNA]; 2-tert-butylhydroquinone inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of TNF protein] 2-tert-butylhydroquinone inhibits the reaction [TNF protein affects the localization of NFKBIA protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein affects the localization of RELA protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:28583816 PMID:32073640 PMID:32565124 PMID:35724838 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions increases expression |
ISO |
2-tert-butylhydroquinone inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]; 2-tert-butylhydroquinone inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] 2-tert-butylhydroquinone results in increased expression of TNFAIP3 mRNA; 2-tert-butylhydroquinone results in increased expression of TNFAIP3 protein |
CTD |
PMID:35724838 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
2-tert-butylhydroquinone inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of AKT1 protein]; 2-tert-butylhydroquinone inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased secretion of HMGB1 protein]; [2-tert-butylhydroquinone co-treated with CSF1 protein co-treated with TNFSF11 protein] results in decreased expression of CSF1R protein; [2-tert-butylhydroquinone co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of HMOX1 protein; [TNFSF11 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of CSF1R protein; [TNFSF11 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of SRC protein; [TNFSF11 protein co-treated with 2-tert-butylhydroquinone] results in increased expression of HMOX1 protein; [TNFSF11 protein co-treated with CSF1 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of CTSK protein; [TNFSF11 protein co-treated with CSF1 protein co-treated with 2-tert-butylhydroquinone] results in decreased expression of NFATC1 protein |
CTD |
PMID:23112101 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tob1 |
transducer of ErbB-2.1 |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of TOB1 mRNA |
CTD |
PMID:16014739 |
|
NCBI chr10:79,163,093...79,165,131
Ensembl chr10:79,160,154...79,165,215
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [hydroquinone results in increased expression of TP53 protein] 2-tert-butylhydroquinone results in increased expression of TP53 protein 2-tert-butylhydroquinone inhibits the reaction [Emodin results in increased expression of TP53 protein] |
CTD |
PMID:35123993 PMID:37393915 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of TRIB3 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression decreases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of TXNRD1 mRNA 2-tert-butylhydroquinone results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:12949356 PMID:16014739 PMID:30806763 PMID:35724838 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
EXP |
2-tert-butylhydroquinone results in increased expression of UGT1A1 mRNA |
CTD |
PMID:20650352 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression multiple interactions increases activity |
EXP ISO |
2-tert-butylhydroquinone results in increased expression of UGT1A6 mRNA AHR protein promotes the reaction [2-tert-butylhydroquinone results in increased expression of UGT1A6 mRNA] 2-tert-butylhydroquinone results in increased activity of UGT1A6 protein |
CTD |
PMID:10220484 PMID:12948865 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of UGT1A9 mRNA |
CTD |
PMID:10220484 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of UGT2B7 mRNA |
CTD |
PMID:10220484 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
2-tert-butylhydroquinone results in increased expression of VCAM1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
2-tert-butylhydroquinone results in decreased expression of VEGFA mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|